A new public exchange-traded fund (ETF) launched, officially offering investors exposure into smaller cannabis companies within the space. Now shareholder hopefuls can get a closer look at the actual holdings in this new index.

Last week, the Investing News Network (INN) reported the launch details for the Horizons Emerging Marijuana Growers Index ETF (AQN:HMJR), which began trading on the Aequitas NEO Exchange on Wednesday (February 14).


“HMJR will exclusively invest in marijuana growers that, in our view, are well-positioned to take part in the global growth of the marijuana sector,” Steve Hawkins, president and Co-CEO of Horizons ETFs said in the NEO statement. “NEO’s support of the budding marijuana industry gave us the confidence to launch this unique product on their market.”

The index will look for companies ranging in between $50 and $500 million worth for their market cap.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

As of Tuesday (February 13), the biggest holdings in this index are two Australian ventures, Cann Group (ASX:CAN) and Auscann Group Holdings (ASX:AC8) representing 8.15 and 7.59 percent in total weight respectively.

The top Canadian holding with a 5.56 percent weight is The Hydropothecary Company (TSXV:THCX).

The ETF is divided with Canadian and Australian companies amounting to 79 and 21 percent of the total holdings respectively, according to the launch documents from Horizons.

New ETF offers investors exposure with smaller cannabis companies

“It is a great honour for INDIVA to be included in this ETF, and we are excited for the exposure this will bring to the company, both for investors and future clients,” Niel Marotta, CEO of INDIVA (TSXV:NDVA) said as part of his company’s announcement.

Scott Boyes, chairman, president, and CEO of MPX Bioceutical said the inclusion for his company in the index will “broaden” the company’s shareholder base and increase investor awareness.

According to Horizon’s documents on HMJR, potential investors of the Horizons Emerging Marijuana Growers Index will have to pay an annual management fee worth 0.85 percent of the ETF’s value.

Here’s a look at the current top holdings for the new index, as of February 13 according to Horizons, to find out the rest of the holdings are, click here.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: INDIVA and Hiku Brands is a client of the Investing News Network. This article is not paid-for content.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less